Artwork

Content provided by The Immune-Mediated Inflammatory Disease Forum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Immune-Mediated Inflammatory Disease Forum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Discussing PsA: Bimekizumab improves patient-reported outcomes and work productivity

32:04
 
Share
 

Manage episode 469983906 series 1044916
Content provided by The Immune-Mediated Inflammatory Disease Forum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Immune-Mediated Inflammatory Disease Forum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the longer-term impact of bimekizumab on patient-reported outcomes, health-related QoL, and work productivity in patients with active PsA who were bDMARD-naïve or had an inadequate response to TNFis for up to 1 year.
  continue reading

360 episodes

Artwork
iconShare
 
Manage episode 469983906 series 1044916
Content provided by The Immune-Mediated Inflammatory Disease Forum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Immune-Mediated Inflammatory Disease Forum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the longer-term impact of bimekizumab on patient-reported outcomes, health-related QoL, and work productivity in patients with active PsA who were bDMARD-naïve or had an inadequate response to TNFis for up to 1 year.
  continue reading

360 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play